Analyst Ratings For Repligen
Portfolio Pulse from Benzinga Insights
Repligen (NASDAQ:RGEN) has received mixed ratings from 6 analysts in the past three months, with 2 bullish and 4 somewhat bullish ratings. The average 12-month price target is $189.17, with a high of $210.00 and a low of $165.00, reflecting a 7.5% decrease in the average target. Analysts from firms like JP Morgan, UBS, Stifel, RBC Capital, and Keybanc have adjusted their ratings and price targets, responding to market conditions and company performance. Repligen, a life sciences company, has seen a revenue decline of -29.66% as of September 30, 2023, but maintains a strong net margin of 12.87% and an exceptional ROA of 0.72%, with a conservative debt-to-equity ratio of 0.21.
December 20, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Repligen has received a range of analyst ratings, with a downward revision in the average price target. Despite a significant revenue decline, the company maintains strong profitability metrics.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty, which could lead to a neutral short-term impact on RGEN's stock price. However, the company's strong profitability metrics may counterbalance the negative revenue growth, leading to a neutral score. The relevance is 100 as the article is directly about Repligen. The importance is set at 85 due to the significant impact analyst ratings can have on stock performance, especially when combined with financial performance data. The confidence level is at 90, reflecting the clear data provided on analyst ratings and financial metrics.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100